EU review of BMS-Celgene deal open for comments
MLex Summary: The EU's review of the acquisition of Celgene by Bristol-Myers Squibb (BMS) is open for comments from interested parties. The European Commission today published a notice inviting feedback within...To view the full article, register now.
Already a subscriber? Click here to view full article